The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

The cGAS-STING signaling pathway has emerged as a major focus in cancer immunotherapy because it stimulates interferon production and enhances antitumor immune responses.

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

The integration of genomic testing into cancer screening enables diagnostics to break away from conventional, one-size-fits-all protocols.

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...

Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these ...

Chennai: One in four Indian breast cancer patients carries inherited genetic variants that raise cancer risk beyond the commonly tested BRCA1 and BRCA.

One in four Breast Cancer patients in India carry inherited genetic risk variants linked to cancer risk, according to a study conducted by the IIT-Madras and Karikinos Healthcare.

A study reveals 1 in 4 Indian breast cancer patients carry inherited genetic variants beyond known BRCA genes, urging broader testing strategies.